CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-12 | Sabag Mark See "Remarks" | Sale | −177,626 | $16.25 | $2.9M | 204,964 |
| 2025-01-28 | Daniell Richard Exec. VP, European Commercial | Grant or award · Restricted Share Units | +183,169 | 183,169 | ||
| 2025-01-28 | Sabag Mark EVP, International Markets | Grant or award · Restricted Share Units | +183,169 | 183,169 | ||
| 2025-01-28 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Grant or award · Restricted Share Units | +183,169 | 183,169 | ||
| 2024-12-20 | MIGNONE ROBERTO Director | Sale | −286,000 | $22.01 | $6.3M | 695,000 |
| 2024-12-02 | Lichtenstein Chen Director | Grant or award · Restricted Share Units | +4,804 | 4,804 | ||
| 2024-11-20 | Fox Christine EVP, Head of U.S. Commercial | Option exercise 10b5-1 | +63,492 | 63,492 | ||
| 2024-11-20 | Fox Christine EVP, Head of U.S. Commercial | Sale 10b5-1 | −19,388 | $16.87 | $327K | 44,104 |
| 2024-11-20 | Fox Christine EVP, Head of U.S. Commercial | Option exercise · Restricted Share Units 10b5-1 | −63,492 | 190,476 | ||
| 2024-09-02 | Shalev Varda Director | Option exercise | +12,872 | 12,872 | ||
| 2024-09-02 | Shalev Varda Director | Option exercise · Restricted Share Units | −12,872 | 0 | ||
| 2024-08-12 | Daniell Richard Exec. VP, European Commercial | Sale | −98,943 | $17.30 | $1.7M | 0 |
| 2024-08-09 | Grant Angus EVP, Business Development | Option exercise 10b5-1 | +12,913 | 12,913 | ||
| 2024-08-09 | Grant Angus EVP, Business Development | Sale 10b5-1 | −4,065 | $17.28 | $70K | 8,848 |
| 2024-08-09 | Grant Angus EVP, Business Development | Option exercise · Restricted Share Units 10b5-1 | −12,913 | 38,739 | ||
| 2024-08-09 | Hughes Eric A See "Remarks" | Sale | −45,060 | $17.38 | $783K | 0 |
| 2024-08-01 | Hughes Eric A See "Remarks" | Option exercise 10b5-1 | +52,742 | 69,597 | ||
| 2024-08-01 | Hughes Eric A See "Remarks" | Sale 10b5-1 | −24,537 | $17.25 | $423K | 45,060 |
| 2024-08-01 | Hughes Eric A See "Remarks" | Option exercise · Restricted Share Units 10b5-1 | −52,742 | 105,486 | ||
| 2024-08-01 | Jover Placid See "Remarks" | Grant or award · Restricted Share Units | +51,311 | 51,311 |
Page 19 of 76 · 1,517 trades